RECURRENT ENDOMETRIAL CANCER
Clinical trials for RECURRENT ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to keep endometrial cancer at bay
Disease control Recruiting nowThis study tests whether a combination of two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from growing. The trial enrolls 32 people with a specific type of cancer that is estrogen-receptor positive and has certain genetic features. Par…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
New drug combo offers hope for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis study tests whether two drugs, pembrolizumab and lenvatinib, can shrink or control recurrent endometrial cancer that did not respond to initial chemotherapy and immunotherapy. About 46 adults with a specific type of uterine cancer (mismatch repair proficient) will receive th…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated May 26, 2026 08:31 UTC
-
New antibody combo aims to shrink hard-to-treat ovarian tumors
Disease control Recruiting nowThis early-phase trial tests an experimental drug called ubamatamab, alone or with another drug (cemiplimab), in people with ovarian or uterine cancer that has come back. The main goals are to check safety, find the best dose, and see if the treatment can shrink tumors. About 890…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:03 UTC